CG oncology
CG oncology
CGON
NASDAQ
36.88
USD
42.61%
About
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC).
Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC.
Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 514.8K |
| Three Month Average Volume | 12.0M |
| High Low | |
| Fifty-Two Week High | 50.23 USD |
| Fifty-Two Week Low | 25.77 USD |
| Fifty-Two Week High Date | 16 Feb 2024 |
| Fifty-Two Week Low Date | 13 May 2024 |
| Price and Volume | |
| Current Price | 36.88 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 7.08% |
| Thirteen Week Relative Price Change | 5.77% |
| Twenty-Six Week Relative Price Change | -23.73% |
| Fifty-Two Week Relative Price Change | -99,999.99% |
| Year-to-Date Relative Price Change | -99,999.99% |
| Price Change | |
| One Day Price Change | 0.55% |
| Thirteen Week Price Change | 13.20% |
| Twenty-Six Week Price Change | -16.14% |
| Five Day Price Change | -0.38% |
| Fifty-Two Week Price Change | -99,999.99% |
| Year-to-Date Price Change | -99,999.99% |
| Month-to-Date Price Change | 10.58% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.91088 USD |
| Book Value Per Share (Most Recent Quarter) | 8.28623 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.91088 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 8.28623 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.25577 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00321 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00999 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.06798 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.16792 USD |
| Normalized (Last Fiscal Year) | -1.06798 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.06798 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.16792 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.06798 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.16792 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.95631 USD |
| Cash Per Share (Most Recent Quarter) | 8.29405 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.06771 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.16537 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.06151 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -10,625 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -9,870.92% |
| Pretax Margin (Last Fiscal Year) | -23,826.96% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -27,180.88% |
| Operating Margin (Trailing Twelve Months) | -12,572.92% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -23,826.96% |
| Net Profit Margin (Trailing Twelve Months) | -9,870.92% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -16.99% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 13 |
| Price to Tangible Book (Most Recent Quarter) | 4 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -552,880,000 |
| Net Debt (Last Fiscal Year) | -187,309,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 12.1K |
| Price to Sales (Trailing Twelve Months) | 3.8K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | 4 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 |
| Current Ratio (Most Recent Quarter) | 48 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -45,679,000 |
| Free Cash Flow (Trailing Twelve Months) | -69,065,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -28.01% |
| Return on Assets (Trailing Twelve Months) | -99,999.99% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -30.63% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -99,999.99% |